^
HLA-A*02:01 positive
|
Uveal Melanoma
|
HLA-A*02:01 positive
|
Uveal Melanoma
|
tebentafusp Sensitive: A1 - Approval
Immunocore Press release - 2 days
|
tebentafusp Sensitive: A1 - Approval
Immunocore Press release - 2 days
|
BRAF V600
|
Melanoma
|
BRAF V600
|
Melanoma
|
dabrafenib + SNR1611 + PDR001 Sensitive: B - Late Trials
J Clin Oncol - 2 weeks
|
dabrafenib + SNR1611 + PDR001 Sensitive: B - Late Trials
J Clin Oncol - 2 weeks
|
TERT promoter mutation + BRAF V600
|
Melanoma
|
TERT promoter mutation + BRAF V600
|
Melanoma
|
BRAF inhibitor + MEK inhibitor Sensitive: C3 – Early Trials
Eur J Cancer - 3 weeks
|
BRAF inhibitor + MEK inhibitor Sensitive: C3 – Early Trials
Eur J Cancer - 3 weeks
|
BRAF V600E
|
Uveal Melanoma
|
BRAF V600E
|
Uveal Melanoma
|
pembrolizumab + binimetinib + encorafenib Sensitive: C4 – Case Studies
S. Karger AG - 4 weeks
|
pembrolizumab + binimetinib + encorafenib Sensitive: C4 – Case Studies
S. Karger AG - 4 weeks
|
BRAF V600
|
Melanoma
|
BRAF V600
|
Melanoma
|
vemurafenib + atezolizumab + cobimetinib Sensitive: A1 - Approval
Expert Rev Anticancer Ther - 3 weeks
|
vemurafenib + atezolizumab + cobimetinib Sensitive: A1 - Approval
Expert Rev Anticancer Ther - 3 weeks
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
dabrafenib Sensitive: A1 - Approval
|
dabrafenib Sensitive: A1 - Approval
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
BRAF V600
|
Melanoma
|
BRAF V600
|
Melanoma
|
binimetinib + encorafenib Sensitive: A1 - Approval
|
binimetinib + encorafenib Sensitive: A1 - Approval
|
BRAF V600K
|
Melanoma
|
BRAF V600K
|
Melanoma
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
trametinib + dabrafenib Sensitive: A1 - Approval
|
No biomarker
|
Melanoma
|
No biomarker
|
Melanoma
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
vemurafenib + cobimetinib Sensitive: A1 - Approval
|
vemurafenib + cobimetinib Sensitive: A1 - Approval
|
BRAF V600
|
Melanoma
|
BRAF V600
|
Melanoma
|
vemurafenib + cobimetinib Sensitive: A1 - Approval
|
vemurafenib + cobimetinib Sensitive: A1 - Approval
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
vemurafenib Sensitive: A1 - Approval
|
vemurafenib Sensitive: A1 - Approval
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
trametinib Sensitive: A1 - Approval
|
trametinib Sensitive: A1 - Approval
|
No biomarker
|
Melanoma
|
No biomarker
|
Melanoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
Melanoma
|
No biomarker
|
Melanoma
|
ipilimumab Sensitive: A1 - Approval
|
ipilimumab Sensitive: A1 - Approval
|
No biomarker
|
Melanoma
|
No biomarker
|
Melanoma
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
PD-L1 underexpression
|
Melanoma
|
PD-L1 underexpression
|
Melanoma
|
ipilimumab Sensitive: A1 - Approval
|
ipilimumab Sensitive: A1 - Approval
|
PD-L1 underexpression
|
Melanoma
|
PD-L1 underexpression
|
Melanoma
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
BRAF V600
|
Melanoma
|
BRAF V600
|
Melanoma
|
dabrafenib Sensitive: A1 - Approval
|
dabrafenib Sensitive: A1 - Approval
|
No biomarker
|
Melanoma
|
No biomarker
|
Melanoma
|
trametinib Resistant: A1 - Approval
|
trametinib Resistant: A1 - Approval
|
BRAF V600
|
Melanoma
|
BRAF V600
|
Melanoma
|
trametinib + dabrafenib Sensitive: A1 - Approval
Clin Cancer Res - 2 weeks
|
trametinib + dabrafenib Sensitive: A1 - Approval
Clin Cancer Res - 2 weeks
|
BRAF V600
|
Melanoma
|
BRAF V600
|
Melanoma
|
trametinib Sensitive: A1 - Approval
|
trametinib Sensitive: A1 - Approval
|
BRAF V600K
|
Melanoma
|
BRAF V600K
|
Melanoma
|
trametinib Sensitive: A1 - Approval
|
trametinib Sensitive: A1 - Approval
|
BRAF V600
|
Melanoma
|
BRAF V600
|
Melanoma
|
vemurafenib Sensitive: A1 - Approval
|
vemurafenib Sensitive: A1 - Approval
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
ipilimumab Sensitive: A1 - Approval
|
ipilimumab Sensitive: A1 - Approval
|
BRAF V600K
|
Melanoma
|
BRAF V600K
|
Melanoma
|
binimetinib + encorafenib Sensitive: A1 - Approval
|
binimetinib + encorafenib Sensitive: A1 - Approval
|
BRAF V600E
|
Melanoma
|
BRAF V600E
|
Melanoma
|
binimetinib + encorafenib Sensitive: A1 - Approval
|
binimetinib + encorafenib Sensitive: A1 - Approval
|
BRAF V600K
|
Melanoma
|
BRAF V600K
|
Melanoma
|
vemurafenib + cobimetinib Sensitive: A1 - Approval
|
vemurafenib + cobimetinib Sensitive: A1 - Approval
|
LDH elevation
|
Melanoma
|
LDH elevation
|
Melanoma
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
No biomarker
|
Melanoma
|
No biomarker
|
Melanoma
|
aldesleukin Sensitive: A1 - Approval
|
aldesleukin Sensitive: A1 - Approval
|
No biomarker
|
Melanoma
|
No biomarker
|
Melanoma
|
BNT111 Sensitive: A1 - Approval
|
BNT111 Sensitive: A1 - Approval
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
TC Sensitive: A2 - Guideline
|
TC Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
TC Sensitive: A2 - Guideline
|
TC Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
ipilimumab Sensitive: A2 - Guideline
|
ipilimumab Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
dacarbazine Sensitive: A2 - Guideline
|
dacarbazine Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
temozolomide Sensitive: A2 - Guideline
|
temozolomide Sensitive: A2 - Guideline
|
BRAF V600
|
Cutaneous Melanoma
|
BRAF V600
|
Cutaneous Melanoma
|
trametinib Resistant: A2 - Guideline
|
trametinib Resistant: A2 - Guideline
|
BRAF V600
|
Cutaneous Melanoma
|
BRAF V600
|
Cutaneous Melanoma
|
vemurafenib + atezolizumab + cobimetinib Sensitive: A2 - Guideline
|
vemurafenib + atezolizumab + cobimetinib Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
temozolomide Sensitive: A2 - Guideline
|
temozolomide Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
dacarbazine Sensitive: A2 - Guideline
|
dacarbazine Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
trametinib Sensitive: A2 - Guideline
|
trametinib Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Uveal Melanoma
|
No biomarker
|
Uveal Melanoma
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
pembrolizumab + ipilimumab Sensitive: A2 - Guideline
|
pembrolizumab + ipilimumab Sensitive: A2 - Guideline
|
BRAF mutation
|
Melanoma
|
BRAF mutation
|
Melanoma
|
dabrafenib + granisetron intravenous Sensitive: A2 - Guideline
|
dabrafenib + granisetron intravenous Sensitive: A2 - Guideline
|
BRAF V600
|
Cutaneous Melanoma
|
BRAF V600
|
Cutaneous Melanoma
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Cutaneous Melanoma
|
BRAF V600E
|
Cutaneous Melanoma
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
NRAS mutation
|
Melanoma
|
NRAS mutation
|
Melanoma
|
binimetinib Sensitive: A2 - Guideline
|
binimetinib Sensitive: A2 - Guideline
|
BRAF V600
|
Cutaneous Melanoma
|
BRAF V600
|
Cutaneous Melanoma
|
binimetinib + encorafenib Sensitive: A2 - Guideline
|
binimetinib + encorafenib Sensitive: A2 - Guideline
|
BRAF V600
|
Melanoma
|
BRAF V600
|
Melanoma
|
BRAF inhibitor + MEK inhibitor Sensitive: A2 - Guideline
|
BRAF inhibitor + MEK inhibitor Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Melanoma
|
NTRK1 fusion
|
Melanoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Melanoma
|
NTRK3 fusion
|
Melanoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Melanoma
|
NTRK2 fusion
|
Melanoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
BRAF V600
|
Cutaneous Melanoma
|
BRAF V600
|
Cutaneous Melanoma
|
dabrafenib + SNR1611 Sensitive: A2 - Guideline
|
dabrafenib + SNR1611 Sensitive: A2 - Guideline
|
BRAF V600
|
Cutaneous Melanoma
|
BRAF V600
|
Cutaneous Melanoma
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
BRAF V600K
|
Cutaneous Melanoma
|
BRAF V600K
|
Cutaneous Melanoma
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
BRAF V600K
|
Cutaneous Melanoma
|
BRAF V600K
|
Cutaneous Melanoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
BRAF V600E
|
Cutaneous Melanoma
|
BRAF V600E
|
Cutaneous Melanoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
BRAF V600K
|
Cutaneous Melanoma
|
BRAF V600K
|
Cutaneous Melanoma
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
BRAF V600E
|
Cutaneous Melanoma
|
BRAF V600E
|
Cutaneous Melanoma
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
ROS1 fusion
|
Melanoma
|
ROS1 fusion
|
Melanoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
KIT exon 11 mutation
|
Melanoma
|
KIT exon 11 mutation
|
Melanoma
|
sunitinib Sensitive: A2 - Guideline
|
sunitinib Sensitive: A2 - Guideline
|
KIT exon 11 mutation
|
Melanoma
|
KIT exon 11 mutation
|
Melanoma
|
nilotinib Sensitive: A2 - Guideline
|
nilotinib Sensitive: A2 - Guideline
|
KIT exon 13 mutation
|
Melanoma
|
KIT exon 13 mutation
|
Melanoma
|
sunitinib Sensitive: A2 - Guideline
|
sunitinib Sensitive: A2 - Guideline
|
BRAF V600K
|
Melanoma
|
BRAF V600K
|
Melanoma
|
dabrafenib Sensitive: A2 - Guideline
|
dabrafenib Sensitive: A2 - Guideline
|
TMB-H
|
Melanoma
|
TMB-H
|
Melanoma
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
ROS1 fusion
|
Melanoma
|
ROS1 fusion
|
Melanoma
|
crizotinib Sensitive: A2 - Guideline
|
crizotinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Melanoma
|
NTRK3 fusion
|
Melanoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Melanoma
|
NTRK1 fusion
|
Melanoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
KIT exon 13 mutation
|
Melanoma
|
KIT exon 13 mutation
|
Melanoma
|
nilotinib Sensitive: A2 - Guideline
|
nilotinib Sensitive: A2 - Guideline
|
BRAF fusion
|
Melanoma
|
BRAF fusion
|
Melanoma
|
sorafenib Sensitive: A2 - Guideline
|
sorafenib Sensitive: A2 - Guideline
|
ALK fusion
|
Melanoma
|
ALK fusion
|
Melanoma
|
crizotinib Sensitive: A2 - Guideline
|
crizotinib Sensitive: A2 - Guideline
|
ALK fusion
|
Melanoma
|
ALK fusion
|
Melanoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
BRAF V600
|
Cutaneous Melanoma
|
BRAF V600
|
Cutaneous Melanoma
|
pembrolizumab + dabrafenib Sensitive: A2 - Guideline
|
pembrolizumab + dabrafenib Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
talimogene laherparepvec Sensitive: A2 - Guideline
|
talimogene laherparepvec Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
CaT Sensitive: A2 - Guideline
|
CaT Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
paclitaxel + albumin-bound paclitaxel + dacarbazine Sensitive: A2 - Guideline
|
paclitaxel + albumin-bound paclitaxel + dacarbazine Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
CVD Sensitive: A2 - Guideline
|
CVD Sensitive: A2 - Guideline
|
BRAF V600E
|
Cutaneous Melanoma
|
BRAF V600E
|
Cutaneous Melanoma
|
binimetinib + encorafenib Sensitive: A2 - Guideline
|
binimetinib + encorafenib Sensitive: A2 - Guideline
|
BRAF V600K
|
Cutaneous Melanoma
|
BRAF V600K
|
Cutaneous Melanoma
|
binimetinib + encorafenib Sensitive: A2 - Guideline
|
binimetinib + encorafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Cutaneous Melanoma
|
BRAF V600E
|
Cutaneous Melanoma
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Cutaneous Melanoma
|
BRAF V600E
|
Cutaneous Melanoma
|
dabrafenib Sensitive: A2 - Guideline
|
dabrafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Cutaneous Melanoma
|
BRAF V600E
|
Cutaneous Melanoma
|
vemurafenib Sensitive: A2 - Guideline
|
vemurafenib Sensitive: A2 - Guideline
|
BRAF V600
|
Cutaneous Melanoma
|
BRAF V600
|
Cutaneous Melanoma
|
pembrolizumab + trametinib Sensitive: A2 - Guideline
|
pembrolizumab + trametinib Sensitive: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
PD1 inhibitor + talimogene laherparepvec Resistant: A2 - Guideline
|
PD1 inhibitor + talimogene laherparepvec Resistant: A2 - Guideline
|
No biomarker
|
Cutaneous Melanoma
|
No biomarker
|
Cutaneous Melanoma
|
ipilimumab + talimogene laherparepvec Sensitive: A2 - Guideline
|
ipilimumab + talimogene laherparepvec Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Cutaneous Melanoma
|
NTRK2 fusion
|
Cutaneous Melanoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
